PML nuclear bodies: regulation, function and therapeutic perspectives

Umut Sahin; Valérie Lallemand-Breitenbach; Hugues de Thé

doi:10.1002/path.4426

PML nuclear bodies: regulation, function and therapeutic perspectives

J Pathol. 2014 Nov;234(3):289-91. doi: 10.1002/path.4426.

Authors

Umut Sahin¹, Valérie Lallemand-Breitenbach, Hugues de Thé

Affiliation

¹ Université Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, Paris, France; INSERM UMR 944, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Institut Universitaire d'Hématologie, Hôpital St. Louis, Paris, France; CNRS UMR 7212, Hôpital St. Louis, Paris, France.

PMID: 25138686
DOI: 10.1002/path.4426

Abstract

PML nuclear bodies (NBs) were first described by electron microscopy and rediscovered through their treatment-reversible disruption in a rare leukaemia. They recruit multiple partner proteins and now emerge as interferon- and oxidative stress-responsive sumoylation factories. NBs mediate interferon-induced viral restriction, enhance proteolysis, finely tune metabolism and enforce stress-induced senescence. Apart from being markers of cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions, including cancer, viral infection or neurodegenerative diseases.

Keywords: PML; RNF4; arsenic; interferon; oxidative stress; p53; senescence.

Publication types

Review

MeSH terms

Animals
Humans
Intranuclear Inclusion Bodies*
Nuclear Proteins*
Promyelocytic Leukemia Protein
Transcription Factors*
Tumor Suppressor Proteins*

Substances

Nuclear Proteins
Promyelocytic Leukemia Protein
Transcription Factors
Tumor Suppressor Proteins
PML protein, human